SPY331.71+1.65 0.50%
DIA271.41+3.00 1.12%
IXIC10,982.19+41.02 0.37%

Morgan Stanley Upgrades Biogen to Overweight, Raises Price Target to $357

Morgan Stanley analyst Matthew Harrison upgrades Biogen (NASDAQ:BIIB) from Underweight to Overweight and raises the price target from $263 to $357.

Benzinga · -
Morgan Stanley analyst Matthew Harrison upgrades Biogen (NASDAQ: BIIB) from Underweight to Overweight and raises the price target from $263 to $357.